文献速递重症综合管理与镇静镇痛复苏、休克与脓毒症

循环粒细胞型髓源性抑制细胞早期扩增预测脓毒症患者院内感染发生

Early Expansion of Circulating Granulocytic Myeloid-derived Suppressor Cells Predicts Development of Nosocomial Infections in Patients with Sepsis.
PubMed 文献 · Am J Respir Crit Care Med · 2017-01-01
一句话结论脓毒症患者早期高水平的粒细胞型髓源性抑制细胞、精氨酸酶1和S100A12与后续院内感染发生相关。

该研究对29例脓毒症患者和15名健康供者进行外周血转录组分析,另前瞻性纳入94例连续脓毒症患者、11例严重程度匹配的ICU患者和67名健康供者进行流式细胞术和功能实验。结果显示脓毒症患者外周血中MDSC抑制功能相关基因(S100A12、S100A9、MMP8、ARG1)上调,CD14negCD15pos低密度粒细胞/粒细胞型(G)-MDSCs在脓毒症患者中特异性扩增(P < 0.001),且G-MDSCs、精氨酸酶1和S100A12初始高水平与后续院内感染发生相关,而M-MDSCs无此关联。结论认为G-MDSCs产生精氨酸酶1与院内感染发生率较高相关,似乎是脓毒症诱导免疫抑制的主要因素。

要点

  • 脓毒症患者中CD14negCD15pos低密度粒细胞/粒细胞型(G)-MDSCs特异性扩增(P < 0.001),而CD14posHLA-DRlow/neg单核型(M)-MDSCs在伴或不伴脓毒症的ICU患者中均扩增。
  • G-MDSCs、精氨酸酶1和S100A12初始高水平与后续院内感染发生相关,而M-MDSCs无此关联。
  • 体外实验中,去除CD14pos和CD15pos细胞可增加脓毒症患者T细胞增殖。
  • G-MDSCs由表达高水平脱颗粒标志物的未成熟和成熟粒细胞组成,特异性负责精氨酸酶1活性。
  • 脓毒症患者血浆中MDSC介质S100A8/A9、S100A12和精氨酸酶1水平显著升高。

适用人群与场景

  • 脓毒症患者(研究纳入94例连续脓毒症患者进行流式细胞术和功能实验)。
  • 严重程度匹配的ICU患者(11例)作为对照。
  • 健康供者(67名)作为对照。

研究设计与关键结果

  • 研究类型:前瞻性队列研究(第二队列)及外周血转录组分析;样本量:第一队列29例脓毒症患者和15名健康供者,第二队列94例连续脓毒症患者、11例严重程度匹配的ICU患者和67名健康供者。
  • 脓毒症患者外周血中MDSC抑制功能相关基因S100A12、S100A9、MMP8和ARG1上调。
  • CD14posHLA-DRlow/neg单核型(M)-MDSCs在伴或不伴脓毒症的ICU患者中扩增,CD14negCD15pos低密度粒细胞/粒细胞型(G)-MDSCs在脓毒症患者中更特异性扩增(P < 0.001)。
  • 脓毒症患者血浆中MDSC介质S100A8/A9、S100A12和精氨酸酶1水平显著升高。
  • 体外去除CD14pos和CD15pos细胞可增加脓毒症患者T细胞增殖。
  • G-MDSCs由表达高水平脱颗粒标志物的未成熟和成熟粒细胞组成,特异性负责精氨酸酶1活性。
  • G-MDSCs、精氨酸酶1和S100A12初始高水平与后续院内感染发生相关,而M-MDSCs无此关联。

证据类型、等级与局限

  • 证据类型:前瞻性队列研究及体外功能实验。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者认为G-MDSCs产生精氨酸酶1与院内感染发生率较高相关,似乎是脓毒症诱导免疫抑制的主要因素。
  • 作者认为M-MDSCs和G-MDSCs强烈促进脓毒症患者T细胞功能障碍。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

RATIONALE: Sepsis induces a sustained immune dysfunction responsible for poor outcome and nosocomial infections. Myeloid-derived suppressor cells (MDSCs) described in cancer and inflammatory processes may be involved in sepsis-induced immune suppression, but their clinical impact remains poorly defined.

OBJECTIVES: To clarify phenotype, suppressive activity, origin, and clinical impact of MDSCs in patients with sepsis.

METHODS: Peripheral blood transcriptomic analysis was performed on 29 patients with sepsis and 15 healthy donors. A second cohort of 94 consecutive patients with sepsis, 11 severity-matched intensive care patients, and 67 healthy donors was prospectively enrolled for flow cytometry and functional experiments.

MEASUREMENTS AND MAIN RESULTS: Genes involved in MDSC suppressive functions, including S100A12, S100A9, MMP8, and ARG1, were up-regulated in the peripheral blood of patients with sepsis. CD14posHLA-DRlow/neg monocytic (M)-MDSCs were expanded in intensive care unit patients with and without sepsis and CD14negCD15pos low-density granulocytes/granulocytic (G)-MDSCs were more specifically expanded in patients with sepsis (P < 0.001). Plasma levels of MDSC mediators S100A8/A9, S100A12, and arginase 1 were significantly increased. In vitro, CD14pos- and CD15pos-cell depletion increased T-cell proliferation in patients with sepsis. G-MDSCs, made of immature and mature granulocytes expressing high levels of degranulation markers, were specifically responsible for arginase 1 activity. High initial levels of G-MDSCs, arginase 1, and S100A12 but not M-MDSCs were associated with subsequent occurrence of nosocomial infections.

CONCLUSIONS: M-MDSCs and G-MDSCs strongly contribute to T-cell dysfunction in patients with sepsis. More specifically, G-MDSCs producing arginase 1 are associated with a higher incidence of nosocomial infections and seem to be major actors of sepsis-induced immune suppression.

来源:Am J Respir Crit Care Med,查看原文。版权归原作者所有。

参考来源

  1. Uhel F, Azzaoui I, Grégoire M, et al. Early Expansion of Circulating Granulocytic Myeloid-derived Suppressor Cells Predicts Development of Nosocomial Infections in Patients with Sepsis. Am J Respir Crit Care Med. 2017. PMID: 28146645. doi:10.1164/rccm.201606-1143OC

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。